Larry Tremaine

Dr. Tremaine has 34 years of experience in the pharmaceutical industry, mainly at Pfizer. There he led a variety of laboratory groups with the Drug Metabolism and preclinical PK (DMPK) discipline, providing experimental data for all small molecule programs. He contributed to the development of successfully approved drugs, including Zoloft, Geodon, Chantix, Eliquis, and Xeljanz. Dr. Tremaine received a Ph.D. in Pharmacology from the University of Minnesota Medical School.